Open AccessInfluence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients
Author(s) -
Montri Chamnanphon,
Rattanaporn Sukprasong,
Andrea Gaedigk,
Weerawat Manosuthi,
Pajaree Chariyavilaskul,
Supeecha Wittayalertpanya,
Napatrupron Koomdee,
Thawinee Jantararoungtong,
Apichaya Puangpetch,
Chonlaphat Sukasem
Publication year - 2021
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s306358
Subject(s) - efavirenz , cyp2b6 , pharmacokinetics , medicine , pharmacology , genotyping , slco1b1 , genotype , drug , therapeutic drug monitoring , population , dosing , cyp2a6 , taqman , human immunodeficiency virus (hiv) , virology , pharmacogenetics , viral load , antiretroviral therapy , cyp3a4 , real time polymerase chain reaction , biology , metabolism , cytochrome p450 , biochemistry , gene , environmental health
Plasma efavirenz (EFV) concentrations within therapeutic levels are essential to successfully treat patients suffering from human immunodeficiency virus (HIV) type 1. In addition to the drug-metabolizing enzyme CYP2B6, other phase II drug-metabolizing enzymes and transporters may have an important role in the pharmacokinetics of EFV. Thus, the influence of phase II drug-metabolizing enzymes and drug transporters on plasma EFV levels was investigated in Thai HIV patients receiving EFV.